235 related articles for article (PubMed ID: 34365577)
1. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
[TBL] [Abstract][Full Text] [Related]
3. CSF1R- and SHP2-Inhibitor-Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor-Associated Macrophages.
Ramesh A; Kumar S; Nandi D; Kulkarni A
Adv Mater; 2019 Dec; 31(51):e1904364. PubMed ID: 31659802
[TBL] [Abstract][Full Text] [Related]
4. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.
Magkouta SF; Vaitsi PC; Pappas AG; Iliopoulou M; Kosti CN; Psarra K; Kalomenidis IT
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067348
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
6. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
7. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Eur J Pharm Sci; 2023 Jun; 185():106427. PubMed ID: 36948408
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model.
Zhang H; Almuqbil RM; Alhudaithi SS; Sunbul FS; da Rocha SRP
Int J Pharm; 2021 Apr; 598():120350. PubMed ID: 33545279
[TBL] [Abstract][Full Text] [Related]
9. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
10. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
[TBL] [Abstract][Full Text] [Related]
11. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
[TBL] [Abstract][Full Text] [Related]
12. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
13. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
[TBL] [Abstract][Full Text] [Related]
14. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
15. Polymersomes-Mediated Delivery of CSF1R Inhibitor to Tumor Associated Macrophages Promotes M2 to M1-Like Macrophage Repolarization.
Rodriguez-Perdigon M; Jimaja S; Haeni L; Bruns N; Rothen-Rutishauser B; Rüegg C
Macromol Biosci; 2022 Aug; 22(8):e2200168. PubMed ID: 35624036
[TBL] [Abstract][Full Text] [Related]
16. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma.
Rohila D; Park IH; Pham TV; Jones R; Tapia E; Liu KX; Tamayo P; Yu A; Sharabi AB; Joshi S
Front Immunol; 2023; 14():1148317. PubMed ID: 37350973
[TBL] [Abstract][Full Text] [Related]
17. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer.
Kulkarni A; Chandrasekar V; Natarajan SK; Ramesh A; Pandey P; Nirgud J; Bhatnagar H; Ashok D; Ajay AK; Sengupta S
Nat Biomed Eng; 2018 Aug; 2(8):589-599. PubMed ID: 30956894
[TBL] [Abstract][Full Text] [Related]
18. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages.
Zhu M; Bai L; Liu X; Peng S; Xie Y; Bai H; Yu H; Wang X; Yuan P; Ma R; Lin J; Wu L; Huang M; Li Y; Luo Y
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600555
[TBL] [Abstract][Full Text] [Related]
19. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
[TBL] [Abstract][Full Text] [Related]
20. Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer.
Chen Y; Gong L; Cao Y; Liu Z; Wang Y; Cheng H; Feng Y; Yao S; Yin Y; Wu Z; Huang Z
J Control Release; 2024 Feb; 366():395-409. PubMed ID: 38184235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
